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Introduction
Pseudomonas aeruginosa, an environmentally ubiquitous
organism, is an opportunistic human pathogen that plays
a key role in Cystic Fibrosis (CF) patients with around
80% of patients colonized by the age of 20 years (Saiman
and Siegel 2004). With an increase in the level of anti-
biotic resistance over the past decade, there has been a
renewed interest in alternatives to antibiotic therapy.
Although in clinical use in Eastern Europe, bacteriophage
therapy has only recently begun to attract attention in the
West with a number of new products being licenced or
currently in clinical trials (Merabishvili et al. 2009).
To successfully produce whole phage based therapeutics,
a number of criteria must be met. These include the ability
to infect a range of bacterial strains as well as the ability to
reduce the overall level of infection (Hanlon 2007). One of
two distinct approaches may be undertaken to create such
a phage preparation: genetic modification (GM) of the
phage genome to broaden specificity and to increase activ-
ity, or the selective breeding of phage, isolating the most
infectious. The former of these two approaches is undoubt-
edly attractive allowing the ability to not only increase the
rate and overall level of bacterial kill but also to provide
genes that when expressed would enhance phage virulence,
e.g., biofilm penetration through the production of an algi-
nate lyase (Hanlon et al. 2001). However, products based
on genetically modified (GM) phages might be more
difficult to bring to market due to the level of regulation
surrounding GM organisms. The latter approach on the
other hand allows for the selection of more virulent phages
on the basis of infectivity (Jassim et al. 1995).
The activity of phages is generally measured using tra-
ditional plating on agar of target bacteria where infection
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Abstract
Introduction: Pseudomonas aeruginosa is an opportunistic pathogen and is the
main cause of respiratory infection in cystic fibrosis patients. Most strains pre-
valent within the UK are resistant to two or more antibiotics leading to the
search for new therapeutic strategies including the use of bacteriophages.
Methods and Results: The infectivity of four bacteriophages was increased
using an enhancement protocol based on the use of pomegranate rind extract.
Their efficacy against 14 Ps. aeruginosa strains was measured using a qualitative
streak test and a novel quantitative assay based on the Bioscreen C microbial
growth analyzer. Streak test analysis illustrated an increase in the lytic activity
of enhanced bacteriophages, whereas Bioscreen analysis showed that both
enhanced and unenhanced bacteriophages failed to meet acceptable levels of
activity in c. 50% of strains tested.
Conclusions: The quantitative Bioscreen C analyzer showed comparable but
not identical results in phage activity and identified significant bacterial re-
growth by 20 h postinfection.
Significance and Impact of the Study: With the resurgence of interest in bacte-
riophage therapy against infectious bacterial diseases, a rapid high throughput
quantitative method for screening phage activity and bacterial resistance is
required. The use of the Bioscreen C analyzer meets these criteria and was
shown to be more stringent than the traditional streak test.
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will be identified by plaque production (Adams 1959).
Plaque morphologies and counts, however, vary yielding
a subjective end point. The traditional streak assay, which
relies on such a protocol is limited in its capacity and
does not provide evidence for the emergence of bacterial
resistance and re-growth (Merabishvili et al. 2009). Both
phage induced lysis and bacterial re-growth can be
followed by turbidometric measurements, offering an
alternative and potentially high throughput method
(Maillard et al. 1996).
In the present study, the efficacy of a novel high through-
put method for measuring phage activity was tested against
four Ps. aeruginosa phages and 14 strains of Ps. aeruginosa
including isolates from CF patients. Phage activity was
concurrently tested with a traditional streak test.
Materials and Methods
Host cells and bacteriophage cultures
Bacterial strains were kindly provided by Dr E Mahen-
thiralingam (School of Biosciences, Cardiff University,
Cardiff, UK) (Table 1). Ps. aeruginosa PAO1 was obtained
from the National Collection of Industrial and Marine
Bacteria (NCIMB, Aberdeen, UK). Ps. aeruginosa NCTC
10332 (reference strain) was obtained from the Health
Protection Agency (London, UK). Four bacteriophages,
C10176-Large (C10176-L), C10176-Small (C10176-S),
GL-1 and L-Phage-Medium (LP-M), were kindly
provided by Prof. GW Hanlon (School of Pharmacy,
University of Brighton, Brighton, UK). Bacterial strains
and bacteriophages were stored at )80C in 10% glycerol.
Bacterial cultures were routinely prepared in tryptone soy
broth (TSB; Oxoid Ltd, Cambridge, UK) and incubated
at 37C for 24 h. Cultures were centrifuged at 2600 g,
resuspended in tryptone sodium chloride (TSC; 1 g l)1
tryptone, 9Æ25 g l)1 NaCl) to a standardized optical
density at 600 nm (OD600) corresponding to 1–3 · 108
CFU ml)1. Bacteriophage suspensions were routinely pre-
pared using the soft overlay agar method (Adams 1959)
with Ps. aeruginosa PAO1 used as the host. Five ml of
phosphate buffered saline (PBS; Sigma, Dorset, UK) was
used to remove the sloppy agar layer containing the
phage. The phage suspension was then centrifuged at
11 000 g for 15 min at 4C and passed through 0Æ45 and
0Æ2 lm membrane filters (Millipore, Cork, Ireland).
Preparation of pomegranate rind extract
Pomegranate rind extract (PRE) was kindly provided by
David Houston (Welsh School of Pharmacy, Cardiff
University, Cardiff, UK) and prepared as described in
Stewart et al. (1998). Briefly, PRE was diluted by adding
1Æ3 ml of PRE in 8Æ7 ml of k buffer immediately prior to
use and 8Æ3 ml added to 16Æ7 ml of a freshly prepared
ferrous sulfate solution (4Æ8 mmol l)1 FeSO4.7H2O). The
solution was protected from light.
Enhancement of Ps. aeruginosa bacteriophage activity
The phage enhancement principle used in this study is
based on the selection of the more virulent phage on the
basis of invasion time. The enhancement protocol was
adapted from Jassim et al. (1995) and is shown in Fig. 1.
Table 1 Pseudomonas aeruginosa strains used in this investigation
Strain name Source Comment
NCTC 10332 NCTC Also known as ATCC 10145. Quality control strain for API products.
Not producing alginate (Edwards and Saunders 2001)
PAO1 Clinical, nonCF Ps. aeruginosa genome sequencing strain (Stover et al. 2000)
C3652* CF Epidemic Manchester CF strain type (Jones et al. 2001)
C3719* CF Epidemic Manchester CF strain type (Jones et al. 2001)
C3786* CF Melbourne Ps. aeruginosa CF strain – unique (Armstrong et al. 2003)
LES 400* CF Liverpool epidemic strain- Hypervirulent Strain predominant
epidemic strain in the UK (Salunkhe et al. 2005; Fothergill et al. 2007)
Midlands-1-9245 (Mids-1) CF Midland 1 epidemic strain
P8959* CF Liverpool epidemic strain- predominant epidemic
strain in the UK (Fothergill et al. 2007)
C1913* CF A55 unique- Unique genotype from Vancouver patients (Lewis et al. 2005)
C2238¤ CF A61 unique- Unique genotype from Vancouver patients (Lewis et al. 2005)
C2846¤ CF A55 unique-Unique genotype from Vancouver patients (Lewis et al. 2005)
C3597¤ CF Nonepidemic Manchester CF strain type (Jones et al. 2001)
C4503¤ CF A55 unique- Unique genotype from Vancouver patients (Lewis et al. 2005)
PAK-SR Research Strain StreptomycinR parent of Fla- ⁄ Pil- mutants of PAK. Sm50
Strains indicated by * are epidemic CF strains. ¤ nonepidemic CF strains.
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The initial exposure time (referred to as enhancement
time) was 15 min and subsequently shortened to 10, 5
and 2Æ5 min.
Streak test assay
The following methodology was adapted from (Merabish-
vili et al. 2009). Ten microlitres of bacterial suspension
(c. 1 · 108 CFU ml)1) was streaked over the surface of a
100 · 100 mm square petri dish (Sterilin Ltd, Caerphilly,
UK) that was previously divided into a 5 · 5 grid and air
dried at room temperature for 15 min. Ten microlitres of
bacteriophage suspension (c. 1 · 107 PFU ml)1) was then
spotted onto each intersection and air dried at room tem-
perature for 1 h. PBS was used as a negative control.
Plates were incubated at 37C for 3 h and a primary
assessment for activity was made on the basis of the
extent of phage lysis. A secondary reading was performed
after a further incubation for 18 h at room temperature
and a score of ‘0’ (no plaque) to ‘+5’ (confluent lysis)
was attributed (Merabishvili et al. 2009) (Fig. 2). Ten sep-
arate experiments were conducted and a final score out of
a maximum value of 50 was calculated.
Bioscreen assay
Three hundred and fifty microlitres of a bacterial suspen-
sion in TSB (c. 1 · 108 CFU ml)1) was added to each
well of a 100 well honeycomb plate (Oy Growth Curves
AB Ltd, Helsinki, Finland) with TSB used as a negative
control. To each well, 50 ll of standardized bacteriophage
suspension (1011 PFU ml)1) was added. This phage ⁄bac-
terial cell ratio was determined in preliminary experi-
ments to give the most appropriate phage activity,
without directly lysing the bacterial cell on initial contact,
thus allowing phage replication inside the host. To
increase the reproducibility of the reading, a total of 10
wells for each phage were inoculated for each honeycomb
plate. The plates were then incubated at 37C for 20 h
and turbidity recorded using a wideband filter (420–
580 nm) with readings taken every 15 min in a Bioscreen
C analyzer (Oy Growth Curves AB Ltd, Helsinki,
Finland). Each reading was preceded by a 10 s shaking
cycle. A total of three independent experiments were per-
formed using fresh bacterial cultures and phage cultures
Initial phage 
suspension 
(unenhanced) 
10 µ l of 1012 PFU ml–1 
15 min enhancement time
Bacterial host 
suspension (PAO1) 
10 µ l of 109 CFU ml–1 
2–3 min contact time 
Selection step 
Addition of PRE (144 µ l) 
Neutralisation of PRE 
Addition of 2% (v/v) Tween 80 in λ-buffer  
(144 µ l) 
Propagation of “enhanced” phages 
Addition of 0·1 ml PAO11 (108 CFU ml–1) and 2·3 
ml TSB  
Incubation for 3–5 h at 37 °C 
Isolation of phages 
(in this schematic 15 min enhancement time)
1
Figure 1 Schematic representation of bacteriophage enhancement
using pomegranate rind extract. 1:Contact time between phages and
bacterial suspension varied (i.e. enhancement time of 2Æ5, 5, 10 and
15 min were used; see text).
CI
Ng
Scl NTV
OI
+/–
Figure 2 Example of a phage streak test plate at secondary reading
stage. Cl – confluent lysis (+5), Ol – overgrowth, bacterial line
completely broken, presence of singular bacterial colonies on spot
(+4), Scl – Semi-confluent lysis- bacterial line not completely broken
(+3), NTV – Multiple small phage plaques (+2), + ⁄ ) Bacterial line just
affected i.e. little observable disruption to bacterial line (+1) and
Ng-negative (0).
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for each repeat. Once completed, the mean optical density
(out of 10 wells) for each sample at each sampling time
was calculated. Bacterial number at 8 and 20 h incubation
time was calculated using a standard graph plotting opti-
cal density reading vs CFU ml)1. Reduction in bacterial
number (expressed as Log10 reduction) following phage
exposure was calculated by comparing bacterial number
recovered after 8 and 20 h incubation from wells exposed
to phage and those not exposed to phages (control)
(Fig. 3).
For this study, phage activity with the Bioscreen C ana-
lyser was measured against set ‘acceptance’ values attrib-
uted to two main parameters: (i) a ‡ 2 log10 decrease in
bacterial number after 8 and 20 h (i.e. measurement of
bactericidal efficacy) and (ii) a time of ‡480 min to reach
a OD420–580 of 0Æ1 above the original OD420–580 (measure-
ment of bacterial re-growth postphage infection) (Fig. 3
and Table 2). Other parameters were also calculated but
did not contribute to the assessment of phage efficacy.
These included the measurement of phage initial lytic
activity indicated by a decrease in OD420–580 within
30 min of phage addition (Fig. 3) and the calculation of
the lytic slope, which indicates the rate of bacterial lysis.
The attribution of set ‘acceptance’ values (Table 2) was
based on a review of the literature for phage activity
(Hanlon et al. 2001; Atterbury et al. 2007; Fu et al. 2010)
and antibiotic dosing times (Van Zanten et al. 2007;
McCoy et al. 2008).
Statistical analysis
Data were analysed for significant differences using a one-
way anova in Minitab 15 (Minitab Ltd, Coventry, UK).
Results
Assessment of phage activity using the streak test
method
Phage activity was enhanced against Ps. aeruginosa PAO1.
Phages showing an increase in activity were then tested
against the different clinical isolates.
The streak test showed an increase in the level of
lytic activity of the four phages against Ps. aeruginosa
PAO1 (Table 3). The largest level of increased lytic
activity against PAO1 was after the first enhancement
step of 15 min (data not shown). The further enhance-
ment steps following 10, 5 and 2Æ5 min contact time
lead to smaller increases in activity (data not shown).
Ultimately, the maximum level of lytic activity against
PAO1 was reached after the final enhancement time of
2Æ5 min for all phages, except for GL-1, for which a
maximum activity was reached after the enhancement
time of 5 min (Table 3). When used against all bacte-
rial isolates, the highest increase in activity was
observed for C10176-L and LP-M and the smallest for
GL-1. For some bacterial strains, notably for the CF
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Figure 3 Representative change in bacterial growth patterns of Pseudomonas aeruginosa strain C1913 following treatment with original and
enhanced C10176-S bacteriophage. (a and b) bacterial reduction at 8 and 20 h respectively. (c) time taken for the OD420–580 to increase by 0Æ1
above the initial OD420-580. Phage treated samples are the mean of three replicates; untreated samples are the mean of six replicates. ( )
Untreated Cultures; ( ) nonPRE treated phage and ( ) PRE treated phage.
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epidemic strain Midlands-1, no increase in phage acti-
vity was observed, whereas only LP-M phage showed
some increase in activity against CF nonepidemic strain
C4503 (Tables 4–7). Overall, C10176-L and LP-M
showed increased levels of activity against 11 strains,
C10176-S against 10 strains and GL-1 against six strains
(Tables 4–7). Surprisingly, all enhanced phages showed
decreased levels of activity against Midlands-1 (data not
shown). Finally, the nonepidemic CF bacterial strains
were overall more susceptible to the enhanced phages
when compared to epidemic strains.
Assessment of phage activity using the Bioscreen C
method
When PAO1 was challenged with phages, a lytic slope
was observed within 30 min of the initial inoculation
for original phages and immediately upon exposure for
Table 2 Summary of the lytic assessment
criteria of Pseudomonas aeruginosa
bacteriophages from Bioscreen C assessment
Evaluation criteria Additional criterion
Log10 reduction Time* (min)
Lysis (min)8 hours 20 hours
‘Acceptance’ value ‡2 ‡2 ‡480 £30
Phage Treatment
No. of bacterial strains meeting the
acceptance value out of 14
GL-1 Non-PRE
treated
3 3 8 7
C10176-S 3 4 8 7
C10176-L 6 6 8 7
LP-M 7 10 8 7
GL-1 PRE
treated
7 7 7 4
C10176-S 6 6 8 4
C10176-L 6 7 6 4
LP-M 7 6 6 4
*Time taken to increase OD420–580 by 0Æ1 above the original OD420–580.
Time taken to induce a lytic slope.
Set ‘acceptance’ value (see text).
Table 3 Comparison of lytic activity of
phages against Pseudomonas aeruginosa
PAO1 between the streak test method and
the Bioscreen C analyzer
Phage treatment
Streak test
(score out of 50)
Bioscreen C analyser
Log10 reduction (CFU ml
)1)
P-values*
Time
(minutes)8 hours 20 hours
C10176-L
None 20 2Æ06 ± 0Æ50 2Æ28 ± 0Æ89 0Æ724 >1200
PRE§ (2Æ5)– 48 3Æ14 ± 0Æ10 3Æ20 ± 0Æ46 0Æ834 >1200
C10176-S
None 29 2Æ04 ± 0Æ52 2Æ31 ± 0Æ83 0Æ662 >1200
PRE (2Æ5) 47 3Æ14 ± 0Æ10 3Æ23 ± 0Æ52 0Æ668 >1200
GL-1
None 20 1Æ95 ± 0Æ51 1Æ24 ± 1Æ10 0Æ367 815 ± 670
PRE (5) 46 2Æ66 ± 0Æ25 2Æ72 ± 0Æ13 0Æ712 >1200
PRE (2Æ5) 43 3Æ15 ± 0Æ11 3Æ18 ± 0Æ40 0Æ905 >1200
LP-M
None 30 2Æ01 ± 0Æ45 2Æ28 ± 0Æ89 0Æ667 >1200
PRE (2Æ5) 45 3Æ01 ± 0Æ30 2Æ97 ± 0Æ55 0Æ917 >1200
Data are based upon the means of three replicates.
*P-values showing differences in log10 reduction at 8 and 20 h.
Time taken to increase OD420–580 by 0Æ1 above the original OD420–580.
None: phage not treated with PRE (i.e. original phage).
§PRE: phage exposed to PRE.
–(time): phage-bacteria contact time (min) before exposure to PRE (see text).
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enhanced phages. However, there was no significant
(P ‡ 0Æ05) change in the rate of OD420–580 decrease per
minute between original and enhanced phages (data
not shown). A lytic slope was not necessarily observed
with all CF isolates exposed to the parent or enhanced
phages (data not shown). Where a decrease OD420–580
was noted (against Ps. aeruginosa LES400, P8959 and
PAK-SR), there was no statistically significantly
Table 4 Summary table of Bioscreen C Data for Pseudomonas aeruginosa strains exposed to C10176-L phage
Bacterial strain
Original phage Enhanced phage
Streak test
(score out of 50)
Bioscreen C analyser
Streak test
(score ⁄ 50)
Bioscreen C analyser
Log10 reduction* Time (minutes) Log10 reduction* Time (minutes)
10332 10 0Æ90 ± 0Æ78 205 ± 10 21 (10) 1Æ90 ± 0Æ65 180 ± 40
C3652 10 0Æ94 ± 0Æ14 590 ± 85 36 (10) 1Æ06 ± 0Æ15 1005 ± 340
C3719 0 0Æ85 ± 0Æ05 565 ± 10 25 (10) 1Æ05 ± 0Æ15 >1200
C3786 44 2Æ58 ± 1Æ05 130 ± 10 –§ 2Æ74 ± 0Æ60 140 ± 10
LES-400 10 1Æ09 ± 0Æ18 1155 ± 80 29 (2Æ5) 0Æ88 ± 0Æ27 860 ± 280
Mids-1 10 ND– 105 ± 45 – ND 140 ± 25
P8959 10 1Æ99 ± 0Æ20 1180 ± 35 27 (10) 1Æ72 ± 0Æ46 770 ± 285
C1913 0 4Æ36 ± 1Æ79 345 ± 55 22 (2Æ5) 3Æ57 ± 2Æ24 240 ± 50
C2238 0 0Æ59 ± 0Æ07 865 ± 135 49 (5) 0Æ59 ± 0Æ14 790 ± 325
C2846 20 2Æ39 ± 0Æ95 305 ± 30 24 (10) 3Æ04 ± 0Æ83 205 ± 40
C3597 47 3Æ78 ± 0Æ82 570 ± 210 50 (10) 2Æ47 ± 0Æ09 185 ± 40
C4503 20 0Æ07 ± 0Æ04 130 ± 10 – 0Æ95 ± 1Æ70 380 ± 440
PAK-SR 16 2Æ90 ± 0Æ22 1085 ± 150 40 (15) 3Æ05 ± 0Æ26 1000 ± 165
Data shown are the mean of three replicates. Bold typeface indicates significant differences.
*Log10 reduction in bacterial number at 8 h.
Time taken to increase OD420–580 by 0Æ1 above the original OD420–580.
(time): phage-bacteria contact time (min) before exposure to PRE (see text).
§Dashes indicate no increase or decrease in lytic activity.
–ND: no reduction in bacterial content determined.
Table 5 Summary table of Bioscreen C Data for Pseudomonas aeruginosa strains exposed to C10176-S phage
Bacterial strain
Original phage Enhanced phage
Streak test
(score out of 50)
Bioscreen C analyser
Streak test
(max. 50)
Bioscreen C analyser
Log10 reduction* Time (minutes) Log10 reduction* Time (minutes)
10332 14 0Æ47 ± 0Æ78 220 ± 30 27 (15) 1Æ64 ± 1Æ20 180 ± 25
C3652 30 0Æ97 ± 0Æ24 900 ± 520 40 (10) 0Æ95 ± 0Æ37 558 ± 200
C3719 30 0Æ89 ± 0Æ24 890 ± 540 31 (15) 0Æ77 ± 0Æ31 485 ± 170
C3786 9 0Æ87 ± 1Æ31 100 ± 25 45 (2Æ5) 3Æ32 ± 0Æ80 145 ± 10
LES-400 14 0Æ91 ± 0Æ24 805 ± 280 30 (2Æ5) 1Æ50 ± .121 980 ± 330
Mids-1 18 ND§ 95 ± 30 –– ND 140 ± 25
P8959 22 1Æ96 ± 0Æ2 1100 ± 85 – 1Æ81 ± 0Æ08 825 ± 145
C1913 30 1Æ50 ± 0Æ33 200 ± 30 – 4Æ49 ± 1Æ05 425 ± 285
C2238 8 0Æ56 ± 0Æ11 805 ± 50 40 (10) 0Æ62 ± 0Æ13 865 ± 340
C2846 25 0Æ76 ± 0Æ67 215 ± 25 30 (10) 2Æ73 ± 1Æ52 215 ± 50
C3597 2 3Æ73 ± 0Æ78 500 ± 280 46 (5) 3Æ39 ± 0Æ59 895 ± 295
C4503 30 ND 140 ± 10 – 0Æ81 ± 1Æ63 370 ± 435
PAK-SR 24 2Æ84 ± 0Æ26 1095 ± 160 46 (5) 3Æ04 ± 0Æ35 1025 ± 100
Data shown are the mean of three replicates. Bold typeface indicates significant differences.
*Log10 reduction in bacterial number at 8 h.
Time taken to increase OD420–580 by 0Æ1 above the original OD420–580.
(time): phage-bacteria contact time (min) before exposure to PRE (see text).
§ND: no reduction in bacterial content determined.
–Dashes indicate no increase or decrease in lytic activity.
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difference (P ‡ 0Æ05) between original and enhanced
phages (data not shown). In the strains where no lytic
slope was observed (e.g. C1913), the growth pattern of
the bacterial isolates was dramatically altered by the
phage (example in Fig. 3) and the final OD420–580 at
20 h was lower following exposure to enhanced phages.
It has to be noted that as our protocol is based on
OD reading, bacterial cell debris following lysis might
have contributed somewhat to the OD values recorded
and as such might have masked initial cell lysis follo-
wing initial phage interaction ⁄ replication in their host.
However, the presence of cell debris cannot explain
solely the dramatic change in bacterial growth pattern
recorded following phage treatment.
When the phage bactericidal activity to PAO1 was eval-
uated, enhanced phages showed a significantly higher
(P £ 0Æ05) level of bacterial reduction compared to their
original counterparts at both 8 and 20 h (Table 3). There
was no significant difference (P ‡ 0Æ05) in the reduction
of bacterial number after 8 and 20 h incubation
(Table 3). There was, however, a significant difference
(P = 0Æ034) between the efficacy of the original and
enhanced phages at 8 h and these results were in accor-
dance to those obtained from the streak test (Table 3). In
the case of GL-1 where a 5 min PRE treatment yielded
the highest score by streak test, there was no significant
difference (P ‡ 0Æ05) in phage activity between the 5 and
2Æ5 min enhancement time (Table 3) when measured with
the Bioscreen. Furthermore, in PAO1, there was no signif-
icant difference in bacterial re-growth following original
and enhanced phage exposure (Table 3).
There was generally no significant difference (P ‡ 0Æ05)
in activity between original and enhanced phages at 8 h
exposure against CF isolates (Tables 4–7), with the excep-
tion of Ps. aeruginosa C3786 and C1913 exposed to
C10176-S (Table 4) and C1913 and C2846 challenged
with GL-1 (Table 6). After 8 h incubation at 37C, all
bacterial strains showed a reduction in bacterial number
when exposed to original or enhanced phages with the
exception of Midlands-1.
Following exposure to phages, all bacterial strains
showed an eventual increase in OD420–580 (Tables 4–7).
This OD420–580 increase is indicative of bacterial
re-growth and potentially indicates the presence of
resistant bacteria to the phage. However, the extent of
OD420–580 increase varied between bacteria ⁄phage combi-
nations. In the majority of cases, the time taken to
increase the OD420–580 by 0Æ1 above the initial OD420–580
was reduced when bacteria were exposed to enhanced
phage (Tables 4–7).
Comparison of activity between the streak test and the
Bioscreen C
Overall, there was some correlation between the streak
test assay and the Bioscreen C assay against PAO1, where
Table 6 Summary table of Bioscreen C Data for Pseudomonas aeruginosa strains exposed to GL-1 phage
Bacterial strain
Original phage Enhanced phage
Streak test
(score out of 50)
Bioscreen C analyser
Streak test
(max. 50)
Bioscreen C analyser
Log10 reduction* Time (minutes) Log10 reduction* Time (minutes)
10332 35 0Æ99 ± 0Æ74 230 ± 35 – 2Æ09 ± 0Æ98 180 ± 25
C3652 34 1Æ23 ± 0Æ17 885 ± 295 38 (10)§ 0Æ90 ± 0Æ20 505 ± 140
C3719 46 0Æ93 ± 0Æ17 585 ± 130 – 0Æ79 ± 0Æ20 455 ± 160
C3786 44 0Æ77 ± 0Æ67 110 ± 30 – 2Æ72 ± 1Æ43 145 ± 10
LES-400 30 1Æ09 ± 0Æ13 1185 ± 25 34 (2Æ5) 0Æ97 ± 0Æ21 940 ± 80
Mids-1 30 ND– 85 ± 20 – ND 140 ± 25
P8959 35 1Æ79 ± 0Æ34 905 ± 175 – 1Æ95 ± 0Æ07 915 ± 25
C1913 6 3Æ30 ± 0Æ85 310 ± 20 22 (2Æ5) 5Æ06 ± 0Æ33 345 ± 90
C2238 23 0Æ51 ± 0Æ08 765 ± 70 40 (10) 0Æ57 ± 0Æ16 840 ± 240
C2846 35 0Æ97 ± 0Æ50 240 ± 15 – 2Æ90 ± 0Æ08 345 ± 275
C3597 50 3Æ80 ± 0Æ78 560 ± 185 – 2Æ98 ± 0Æ19 495 ± 300
C4503 34 ND 140 ± 20 – 0Æ90 ± 1Æ52 350 ± 400
PAK-SR 30 2Æ78 ± 0Æ23 >1200 46 (2Æ5) 2Æ98 ± 0Æ31 1020 ± 40
Data shown are the mean of three replicates. Bold typeface indicates significant differences.
*Log10 reduction in bacterial number at 8 h.
Time taken to increase OD420–580 by 0Æ1 above the original OD420–580.
Dashes indicate no increase or decrease in lytic activity.
§ (time): phage-bacteria contact time (min) before exposure to PRE (see text).
–ND: no reduction in bacterial content determined.
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all enhanced phages with the exception of GL-1 showed
the highest reduction of bacterial number with the
Bioscreen C (Table 3). This fact corresponded to the
highest scores achieved with the streak test (Table 3).
However, with enhanced GL-1, the largest reduction in
bacterial number was obtained after an enhancement
time of 2Æ5 min, compared to the highest score on the
streak test that was obtained after a 5 min enhancement
(Table 3). When comparing the time taken for PAO1 to
re-grow to an OD420–580 value of 0Æ1 higher than the
initial OD420–580, it was found that for all phages,
except GL-1, bacteria treated with both original and
enhanced phages took >1200 min to reach this value
(Table 3).
When the activity of phages was assessed against CF
isolates, the level of correlation between the streak test
and the reduction of bacterial number from the Bioscreen
C method depended upon phage ⁄bacterial strain. A good
correlation was observed with LP-M and two strains,
C10176-L and five strains, GL-1 and six strains and
C10176-S and seven strains (Tables 4–7). For all the
other phage ⁄bacteria combinations, however, the level of
reduction in bacterial number at 8 h was not significantly
different (P ‡ 0Æ05) when exposed to the original or the
enhanced phages.
When phage performance was compared to the set
‘acceptance’ values, it was observed that an ‘acceptable’
status was achieved against 50% or less strains (Table 2).
However, enhanced phages appeared to have a better
activity than the original phage although bacterial
re-growth was faster in many bacteria.
Discussion
With the renewed interest in bacteriophage therapy for a
variety of conditions ranging from Ps. aeruginosa infec-
tions in cystic fibrosis patients to the use of bacterio-
phages to reduce the level of Salmonella colonization of
broiler chickens (Atterbury et al. 2007), there is a need
for a high throughput method, which is both sensitive
and quantitative.
Although a successful phage product does not hinge on
the initial screening of activity, the selection of phages
may be enhanced by efficient and quantitative screening
methods to ensure maximum activity against the widest
host range. Here, we have shown that both the streak
plate method and the Bioscreen method produced similar
results, at least with phages showing a large increase in
activity. Although the streak test provides adequate quali-
tative data for initial screening in the form of a single
number, it does not provide the quantitative data that
would be needed to select phages for practical applica-
tions. Conversely, the data generated by the Bioscreen C
analyser allows for the assessment of multiple criteria.
These criteria, however, should not be taken individually,
but should instead be combined, and phages selected on
the basis of increased characteristics between all criteria
combined. Our assay relied on the calculation of bacterial
Table 7 Summary table of Bioscreen C Data for Pseudomonas aeruginosa strains exposed to LP-M phage
Bacterial strain
Original phage Enhanced phage
Streak test
(score out of 50)
Bioscreen C analyser
Streak test
(max. 50)
Bioscreen C analyser
Log10 reduction* Time (minutes) Log10 reduction* Time (minutes)
10332 32 0Æ87 ± 0Æ56 200 ± 20 – 2Æ01 ± 0Æ80 170 ± 30
C3652 22 1Æ08 ± 0Æ02 880 ± 280 35 (10)§ 0Æ92 ± 0Æ32 505 ± 275
C3719 20 0Æ95 ± 0Æ24 >1200 31 (10) 0Æ76 ± 0Æ29 450 ± 250
C3786 40 3Æ03 ± 1Æ02 130 ± 20 42 (2Æ5) 2Æ70 ± 0Æ99 140 ± 10
LES-400 30 1Æ08 ± 0Æ19 1155 ± 80 – 0Æ91 ± 0Æ23 940 ± 320
Mids-1 10 ND– 115 ± 40 – ND 135 ± 15
P8959 20 2Æ03 ± 0Æ17 >1200 26 (10) 1Æ76 ± 0Æ28 830 ± 285
C1913 0 5Æ57 ± 0Æ45 545 ± 115 22 (10) 4Æ84 ± 0Æ86 350 ± 205
C2238 20 0Æ77 ± 0Æ09 >1200 50 (5) 0Æ51 ± 0Æ17 705 ± 370
C2846 43 3Æ00 ± 0Æ36 305 ± 10 50 (10) 3Æ01 ± 0Æ31 200 ± 40
C3597 43 3Æ90 ± 0Æ82 605 ± 85 50 (10) 2Æ66 ± 0Æ26 220 ± 60
C4503 10 ND 130 ± 10 21 (10) 0Æ83 ± 1Æ54 335 ± 360
PAK-SR 4 2Æ95 ± 0Æ26 995 ± 75 42 (2Æ5) 2Æ85 ± 0Æ33 950 ± 55
Data shown are the mean of three replicates. Bold typeface indicates significant differences.
*Log10 reduction in bacterial number at 8 h.
Time taken to increase OD420–580 by 0Æ1 above the original OD420–580.
Dashes indicate no increase or decrease in lytic activity.
§ (time): phage-bacteria contact time (min) before exposure to PRE (see text).
–ND: no reduction in bacterial content determined.
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number from a pre-established OD ⁄TVC graph. Such
extrapolation of bacterial number has its limitation as the
OD ⁄TVC graph is not linear above an OD value of c. 0Æ8.
At best, this limitation means that our bacterial number
calculated from OD value >0Æ8 might have been underes-
timated. However, the conversion of OD value in bacte-
rial number, and the subsequent calculation of Log10
reduction, enables the direct comparison of phage activity
between strains that show different growth kinetic to be
established. Our method aimed to provide criterion to
compare phage activity against multiple bacterial strains
that might show different growth characteristic. Although,
the conversion of OD values to bacterial number has its
drawbacks, our results proved to be reproducible and
enabled phage activity to be effectively compared.
In this manuscript, two methods were compared and
some similarities were observed. It has to be noted that
the parameters used in the two methodologies were
different, notably the different phage: bacteria ratio,
the incubation temperature following exposure and the
media. These parameters might have contributed to the
differences in results observed. The parameters used with
the Bioscreen were developed in preliminary experiments
and chosen as they provided the best results. The parame-
ters used in the traditional streak test are those described
in the literature and used routinely. The main objective
of this paper was to report an automated method to
improve on the traditional streak test. The main practical
difference between the two methods remains with the
number of bacteria ⁄phage combination that can be tested.
With the streak test, a maximum of four phage combina-
tions and one set of controls (five replicates per bacterial
line) against a single bacterial species could be tested in
any one experiment. However, with the Bioscreen assum-
ing the same number of replicates, a maximum of 18
phage combinations could be investigated showing that
the Bioscreen has a higher throughput. In addition, the
Bioscreen method provided important quantitative infor-
mation on bacterial re-growth following phage exposure
over a 20 h period.
In this study, four Ps. aeruginosa bacteriophages were
confirmed to possess activity against multiple strains of
Ps. aeruginosa including some of the more prevalent
strains within the UK (Salunkhe et al. 2005; Fothergill
et al. 2007). Result variability is most probably caused by
the inherent variability that is associated with both bacte-
rial and bacteriophage growth despite initial standardiza-
tion of bacterial content. The differences in susceptibility
of the phages may be a result in part to the binding effi-
cacy of the phage to the target cell (Hart et al. 1994) and
also the growth rates of the strains tested. The nature of
the PRE treatment also accounts for a lack of increase in
both rate and level of kill as it was originally designed to
select bacteriophages on the basis of invasion time rather
than other factors (Jassim et al. 1995).
The use of the Bioscreen C analyzer produced a quick
real-time assessment of bacteriophage activity. It allows
the rapid visualization of bacterial lysis demonstrating
phage activity although measurement of the rate of lysis
was shown not to be a reliable criterion for the compari-
son of lytic activity. Measurement of OD in the Bioscreen
assay is automated and does not rely on human qualita-
tive assessment on plaque formation as in the streak assay
(Merabishvili et al. 2009) and was shown to be more
stringent compared to the streak test and provided quan-
titative results within 8 h. In comparison, the streak test
method can take up to 24 h (Merabishvili et al. 2009).
The Bioscreen method could be further refined with the
use of metabolic assays to assess the level of bacterial
viability (Kuda and Yano 2003; Cerca et al. 2005) or
potentially bioluminescent mutants (Marques et al. 2005;
Jassim and Griffiths 2007; Thorn et al. 2007), which pro-
vide direct measurements of bacterial viability, ultimately
increasing the sensitivity of this OD-based quantitative
assay.
The set ‘acceptance’ values used in this study aim to
ensure that selected phages possess acceptable properties
to be used for therapy. The phages used in this study
meet these criteria in 50% or less of strains tested, imply-
ing that their activity is not yet sufficient to be applied to
therapeutics. These ‘acceptance’ values were set after a
review of the literature and taken into account antibiotic
dosing to prevent bacterial re-growth. It is conceivable
that our values are too stringent and might need to be
revised. To this aim the testing of phages that are cur-
rently undergoing licencing or already licenced for human
applications would be of benefit.
The Bioscreen method is an in vitro set up and phage
behaviour in vitro might be different from their behaviour
in situ. The chemical and physical parameters used in the
Bioscreen set up (e.g. growth media, temperature; %
CO2) can be modified to represent better conditions
found in practice.
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